Payment overview · 2025
General Payments
$785.23
44 reported records · 21 companies
Healthcare provider profile · identity verified
Frederick Charles Carroll, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT VERNON, OH · NPI 1962431957
Verified facts
What the public records show
CMS Open Payments records show Frederick Charles Carroll, M.D. received $785.23 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.59 | 20.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.06 | 10.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.21 | 9.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.10 | 8.9% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $54.56 | 7.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.63 | 5.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.39 | 5.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.06 | 4.2% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $24.35 | 3.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.83 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.08 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.07 | 2.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.68 | 2.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.92 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.49 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.41 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.59 | 2.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.89 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.46 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $785.23 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.05 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $70.10 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $54.56 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.74 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.08 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.39 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $24.44 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 465 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 124 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 177 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
143 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
180 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1172 | 280 |
| Omeprazole | Omeprazole | 1123 | 238 |
| Gabapentin | Gabapentin | 1115 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 962 | 206 |
| Losartan Potassium | Losartan Potassium | 931 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 901 | 203 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 660 | 140 |
| Furosemide | Furosemide | 634 | 170 |
| Lisinopril | Lisinopril | 621 | 150 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 572 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 528 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 524 | 122 |
| Carvedilol | Carvedilol | 511 | 105 |
| Escitalopram Oxalate | Escitalopram Oxalate | 481 | 87 |
| Montelukast Sodium | Montelukast Sodium | 480 | 114 |
| Eliquis | Apixaban | 465 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 92 |
| Prednisone | Prednisone | 465 | 255 |
| Famotidine | Famotidine | 453 | 97 |
| Metformin Hcl | Metformin Hcl | 439 | 100 |
| Trazodone Hcl | Trazodone Hcl | 436 | 107 |
| Potassium Chloride | Potassium Chloride | 430 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 424 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 408 | 83 |
| Alprazolam | Alprazolam | 402 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 390 | 97 |
| Baclofen | Baclofen | 361 | 105 |
| Tramadol Hcl | Tramadol Hcl | 359 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 342 | 93 |
| Pioglitazone Hcl | Pioglitazone Hcl | 339 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 335 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 323 | 55 |
| Buspirone Hcl | Buspirone Hcl | 317 | 64 |
| Alendronate Sodium | Alendronate Sodium | 314 | 84 |
| Ropinirole Hcl | Ropinirole Hcl | 297 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 284 | 51 |
| Mirtazapine | Mirtazapine | 283 | 60 |
| Meloxicam | Meloxicam | 277 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 275 | 68 |
| Sertraline Hcl | Sertraline Hcl | 267 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 266 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 92 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 251 | 35 |
| Spironolactone | Spironolactone | 241 | 56 |
| Ozempic | Semaglutide | 233 | 42 |
| Simvastatin | Simvastatin | 219 | 45 |
| Propranolol Hcl | Propranolol Hcl | 218 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 217 | 33 |
| Aripiprazole | Aripiprazole | 214 | 49 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 213 | 55 |
| Allopurinol | Allopurinol | 212 | 49 |
| Clonazepam | Clonazepam | 194 | 27 |
| Glimepiride | Glimepiride | 192 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 187 | 34 |
| Azithromycin | Azithromycin | 186 | 98 |
| Oxycodone Hcl | Oxycodone Hcl | 183 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 181 | 40 |
| Xarelto | Rivaroxaban | 180 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 179 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 179 | 39 |
| Topiramate | Topiramate | 178 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 177 | 41 |
| Celecoxib | Celecoxib | 175 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 173 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 164 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 162 | 36 |
| Pregabalin | Pregabalin | 162 | 39 |
| Memantine Hcl | Memantine Hcl | 158 | 31 |
| Donepezil Hcl | Donepezil Hcl | 157 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 156 | 38 |
| Ibuprofen | Ibuprofen | 155 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 151 | 42 |
| Ezetimibe | Ezetimibe | 144 | 36 |
| Symbicort | Budesonide/Formoterol Fumarate | 143 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 138 | 85 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 42 |
| Lorazepam | Lorazepam | 134 | 28 |
| Metformin Hcl Er | Metformin Hcl | 133 | 31 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 132 | 22 |
| Amoxicillin | Amoxicillin | 130 | 70 |
| Januvia | Sitagliptin Phosphate | 127 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 126 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 125 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 125 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 124 | 34 |
| Synthroid | Levothyroxine Sodium | 124 | 28 |
| Farxiga | Dapagliflozin Propanediol | 118 | 26 |
| Atenolol | Atenolol | 114 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 23 |
| Ondansetron Odt | Ondansetron | 111 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 108 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 108 | 25 |
| Finasteride | Finasteride | 108 | 31 |
| Jardiance | Empagliflozin | 107 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 106 | 27 |
| Diazepam | Diazepam | 105 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 76 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 25 |
| Nystatin | Nystatin | 102 | 45 |
| Warfarin Sodium | Warfarin Sodium | 100 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 99 | 29 |
| Fluconazole | Fluconazole | 99 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 29 |
| Fenofibrate | Fenofibrate | 97 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 19 |
| Glipizide Er | Glipizide | 92 | 14 |
| Risperidone | Risperidone | 91 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 59 |
| Myrbetriq | Mirabegron | 80 | 18 |
| Clonidine Hcl | Clonidine Hcl | 78 | 17 |
| Colestipol Hcl | Colestipol Hcl | 78 | 30 |
| Bupropion Xl | Bupropion Hcl | 77 | 15 |
| Midodrine Hcl | Midodrine Hcl | 76 | 18 |
| Temazepam | Temazepam | 75 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 74 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 74 | suppressed |
| Lovastatin | Lovastatin | 73 | 18 |
| Methotrexate | Methotrexate Sodium | 73 | 12 |
| Lamotrigine | Lamotrigine | 72 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 72 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 44 |
| Clonidine | Clonidine | 69 | suppressed |
| Glipizide | Glipizide | 69 | 20 |
| Cephalexin | Cephalexin | 66 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 17 |
| Olanzapine | Olanzapine | 65 | 13 |
| Divalproex Sodium | Divalproex Sodium | 63 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 63 | suppressed |
| Tradjenta | Linagliptin | 63 | suppressed |
| Cilostazol | Cilostazol | 62 | 15 |
| Methylprednisolone | Methylprednisolone | 62 | 53 |
| Sucralfate | Sucralfate | 62 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 17 |
| Imipramine Hcl | Imipramine Hcl | 61 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 60 | 48 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Nifedipine Er | Nifedipine | 59 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 11 |
| Trimethoprim | Trimethoprim | 58 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | 13 |
| Atomoxetine Hcl | Atomoxetine Hcl | 56 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 28 |
| Estradiol | Estradiol | 56 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | 15 |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Pilocarpine Hcl | Pilocarpine Hcl | 53 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 53 | 12 |
| Lidocaine | Lidocaine | 52 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 51 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 51 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 51 | 14 |
| Valacyclovir | Valacyclovir Hcl | 51 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Mounjaro | Tirzepatide | 48 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 20 |
| Promethazine Hcl | Promethazine Hcl | 47 | 18 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 45 | suppressed |
| Carisoprodol | Carisoprodol | 45 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 45 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 45 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 13 |
| Chlorthalidone | Chlorthalidone | 44 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 13 |
| Labetalol Hcl | Labetalol Hcl | 43 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 42 | 11 |
| Nitroglycerin | Nitroglycerin | 42 | 27 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Klor-Con M20 | Potassium Chloride | 40 | suppressed |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 19 |
| Valsartan | Valsartan | 38 | suppressed |
| Colchicine | Colchicine | 37 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Acyclovir | Acyclovir | 36 | suppressed |
| Lactulose | Lactulose | 36 | 14 |
| Meclizine Hcl | Meclizine Hcl | 36 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | 13 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 33 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 33 | 12 |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 13 |
| Ketoconazole | Ketoconazole | 32 | 23 |
| Lithium Carbonate | Lithium Carbonate | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | 13 |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 22 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | 11 |
| Metronidazole | Metronidazole | 29 | 18 |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 13 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 19 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 25 | 17 |
| Linzess | Linaclotide | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | 11 |
| Cartia Xt | Diltiazem Hcl | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 11 |
| Metolazone | Metolazone | 24 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | 13 |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dilantin | Phenytoin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Matzim La | Diltiazem Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $785.23 · 44 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, Azstarys, CAMZYOS, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, INCEPTIV, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, Ohtuvayre, Ozempic, PROLIA, QULIPTA, Rybelsus, SPRAVATO, SYNTHROID, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZENPEP, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error